Flibanserin or pink pill is a drug that is sold under the trade name Addyi and is used
for the treatment of pre-menopausal women with hypoactive sex desire disorder (HSDD).
Flibanserin increases the number of satisfying sexual events per month by approximately one
and a half over placebo. Unlike Viagra which increases blood flow all over the body of a
man, Flibanserin modifies serotonin which is a message-carrying chemical in the brain of a
woman. It is important to note that the FDA had rejected the approval of the drug twice in the
years 2010 and 2013 under the administration of its old manufacturer, Boehringer Ingelheim.
Flibanserin was later approved in the year 2015 by the Food and Drug Administration (FDA)
to treat Hypoactive Sexual Desires Disorder (HSDD) in premenopausal women. Flibanserin or pink pill
One of the reasons that compelled the FDA agency to approve the use of the drug is the campaign dabbed "Eve the Score". In the campaign, the new manufacturer Sprout Pharmaceuticals claimed that men with sexual dysfunctions have several drugs to choose from while women have none (English, Muhleisen, & Rey, 2017).
Before the approval of the drug, the HSDD was recognized as a distinct sexual function
disorder for more than 30 years. Flibanserin was removed from the Diagnostic and Statistical
Manual of Mental Disorders in the year 2013 and was instead replaced with female sexual
interest/arousal disorder (FSIAD). The women who use
Flibanserin are advised to avoid taking alcohol because doing so causes sudden fainting. This
paper aims to discuss the effectiveness and health risk of Flibanserin. Flibanserin or pink pill;
Flibanserin was originally meant for the treatment of depressive disorders such as
anxiety disorders and chronic pain before being repurposed for the treatment of HSDD. The
former developmental code of the drug is BIMT-17. The approval of the drug was first rejected in 2010 by the FDA citing inadequate risk-benefit ratio. Flibanserin was later approved on June 4, 2015, with a condition that the manufacturer would take an initiative of informing women of the drug’s side effects. Flibanserin or pink pill;